Regulatory FDA clears at-home start dose for Alzheimer’s drug Leqembi PharmaphorumThe FDA has cleared Eisai and Biogen's Leqembi Iqlik subcutaneous injection as a starting dose, removing the need for regular infusion clinic visits.NeuroscienceRead full story pharminent July 14, 2026 (Last updated: July 15, 2026) Pharmaphorum The FDA has cleared Eisai and Biogen’s Leqembi Iqlik subcutaneous injection as a starting dose, removing the need for regular infusion clinic visits. Neuroscience Read full story Post navigation Previous: Cellares and Sonoma partner to automate cell therapy manufacturingNext: Novartis and Chai Discovery collaborate on antibody identification Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026